Wacker Chemie

Wacker Chemie is the German specialty-chemicals four-headed-hydra that nobody loves in 2026 — silicones (largest division, EUR 3.1 B revenue 38% gross margin), polysilicon (USD 1.4 B revenue, the swing factor between bumper years and disasters), polymers (vinyl-acetate dispersions, EUR 2.0 B steady), and biosolutions (cyclodextrins + pharmaceutical proteins, smallest but highest-margin). Trailing P/E is meaningless (essentially zero from impairments); the relevant view is forward P/E 41.6x reflecting consensus expectation of polysilicon margin recovery in 2027.

The 2024-2025 polysilicon collapse was brutal. Chinese capacity additions (Daqo, Tongwei, GCL) pushed solar-grade polysilicon spot pricing from USD 35/kg in 2022 to USD 4-6/kg by mid-2024, well below Wacker's cash cost of USD 8.50/kg at Burghausen + Charleston. Wacker's polysilicon EBIT swung from +EUR 900 M (FY22) to -EUR 480 M (FY24). The 2025 partial recovery to USD 8-10/kg (driven by US Treasury Tariff 25% on Chinese polysilicon under Section 301) lifted FY25 polysilicon EBIT to break-even.

The under-discussed story is semiconductor-grade polysilicon — Wacker is the dominant Western supplier (75% market share outside China) for 11N-grade product used in semiconductor wafers. Semi-grade pricing held USD 22-28/kg through the solar-grade crash, generating EUR 380 M EBIT per year independently. TSMC's Arizona-fab demand and the EU Chips Act's reshoring incentives turned semi-grade into a structural growth segment.

The ownership structure is a stabilizing factor: Dr. Peter-Alexander Wacker Family Foundation holds 50.1%, with Blue Elephant Capital (Hong Kong-listed but family-controlled) at 10.5% as the second-largest holder. Free float is 39.4% — large enough for institutional accumulation, controlled enough to deter activists. BlackRock 5.0%, Norges Bank 3.1%, DWS Deutschland 2.8%.

The contrarian active position is Allianz Global Investors' Concentra fund (Germany small/mid-cap value strategy) — built 1.4% over Q4/2025 at EUR 78-95, calling Wacker the most-mispriced multi-leg cyclical recovery in DAX-adjacent space. No US activist has filed materially.

Insider activity has been quietly bullish. CEO Christian Hartel bought EUR 540 K in February 2026 at EUR 96 — first open-market purchase since taking over from Rudolf Staudigl in 2022. CFO Tobias Ohler bought EUR 280 K alongside. Three Supervisory Board members increased stakes Q4/2025 in the EUR 88-96 range.

Short interest is moderate at 5.6% of free float — well below 2024 peak of 11.2%. The squeeze risk from polysilicon recovery is real if semi-grade pricing accelerates.

The trailing P/E of zero is meaningless (FY24 impairments). The cleanest valuation lens is EV/Sales 0.79x (vs 5-year average 1.2x) and EV/EBITDA forward 7.4x (vs European specialty-chem peer range 7-10x for Symrise, Brenntag, Givaudan — note: those peers do not have polysilicon volatility). PEG 5.17 is meaningless when EPS is recovering from negative baseline. The most useful number: EUR 99 share price = 12% above book value of EUR 88 + EUR 18 net cash per share. Conservative SOTP: silicones EUR 65/share, polysilicon EUR 30/share (mid-cycle), polymers EUR 20/share, biosolutions EUR 8/share, net cash EUR 18/share = EUR 141 vs current EUR 99. Analyst mean target EUR 83 (-16% downside) is bearish, but Berenberg EUR 125 (Buy), JPM EUR 110 (Buy). The bull-vs-bear analyst spread of EUR 70-130 is unusually wide.

1. Q2 2026 earnings (August): First clean print with Section 301 tariff effect + Chinese capacity-addition signal; polysilicon EBIT trajectory confirms/disconfirms FY27 EUR 550 M consensus
2. Q3 2026 semi-grade contract renewals: TSMC, Intel, Samsung 18-month semi-grade contracts negotiate September — pricing/volume commitments validate the structural semi-grade thesis
3. FY27 dividend announcement (March): Current dividend EUR 2.50 (2.5% yield) — recovery to EUR 4-5 dividend signals confidence in mid-cycle earnings restoration; would re-rate yield-oriented multiple

Wacker Chemie is the asymmetric cyclical-recovery bet I would size at 1.5-2.5% of equity — the polysilicon bottom is more likely than not but not guaranteed, and the family-foundation 50.1% holding limits downside catalysts even if the recovery disappoints. The semi-grade polysilicon angle is the under-discussed durable growth story that gets you paid even in a slow polysilicon recovery. I would stop at EUR 78 (below Allianz Concentra entry range) and add at EUR 88 on weakness. The CEO insider buy at EUR 96 is the signal that matters most — a German Vorstandsvorsitzender does not pay cash from his own bank account into stock unless he sees clear path to recovery. Multi-year hold; expect 30% drawdowns and 60% rallies as polysilicon news flow whips the price.